CN111041102A - 一种对d-柠檬烯混合物抗肿瘤活性敏感患者的筛选方法 - Google Patents
一种对d-柠檬烯混合物抗肿瘤活性敏感患者的筛选方法 Download PDFInfo
- Publication number
- CN111041102A CN111041102A CN201911320522.9A CN201911320522A CN111041102A CN 111041102 A CN111041102 A CN 111041102A CN 201911320522 A CN201911320522 A CN 201911320522A CN 111041102 A CN111041102 A CN 111041102A
- Authority
- CN
- China
- Prior art keywords
- gene
- limonene
- mixture
- cancer
- difference
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 title claims abstract description 140
- 239000000203 mixture Substances 0.000 title claims abstract description 92
- 238000012216 screening Methods 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims abstract description 18
- 230000000259 anti-tumor effect Effects 0.000 title claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 95
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 41
- 201000011510 cancer Diseases 0.000 claims abstract description 38
- 230000014509 gene expression Effects 0.000 claims abstract description 26
- 230000001093 anti-cancer Effects 0.000 claims abstract description 11
- 238000012545 processing Methods 0.000 claims abstract description 3
- 210000004027 cell Anatomy 0.000 claims description 25
- 230000004083 survival effect Effects 0.000 claims description 14
- 230000006870 function Effects 0.000 claims description 8
- 230000008827 biological function Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 238000000205 computational method Methods 0.000 claims description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 230000004709 cell invasion Effects 0.000 claims description 2
- 230000012292 cell migration Effects 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229930003944 flavone Natural products 0.000 claims description 2
- 150000002212 flavone derivatives Chemical class 0.000 claims description 2
- 235000011949 flavones Nutrition 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 2
- 238000004364 calculation method Methods 0.000 abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Zoology (AREA)
- Theoretical Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Artificial Intelligence (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911320522.9A CN111041102A (zh) | 2019-12-19 | 2019-12-19 | 一种对d-柠檬烯混合物抗肿瘤活性敏感患者的筛选方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911320522.9A CN111041102A (zh) | 2019-12-19 | 2019-12-19 | 一种对d-柠檬烯混合物抗肿瘤活性敏感患者的筛选方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111041102A true CN111041102A (zh) | 2020-04-21 |
Family
ID=70238130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911320522.9A Pending CN111041102A (zh) | 2019-12-19 | 2019-12-19 | 一种对d-柠檬烯混合物抗肿瘤活性敏感患者的筛选方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111041102A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111956632A (zh) * | 2020-09-27 | 2020-11-20 | 上海市同仁医院 | 一种抗肿瘤的组合物及其应用 |
CN114107493A (zh) * | 2021-03-29 | 2022-03-01 | 上海市同仁医院 | 一种筛选对于右旋柠檬烯治疗敏感的肺腺癌患者的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04351950A (ja) * | 1991-05-30 | 1992-12-07 | Mitsubishi Electric Corp | 臭気感応材料 |
CN101095944A (zh) * | 2007-07-10 | 2008-01-02 | 上海市肿瘤研究所 | 一种预防和治疗前列腺炎穴位缓释贴片及其制品、制备方法和用途 |
CN106727450A (zh) * | 2016-12-29 | 2017-05-31 | 上海交通大学医学院 | 右旋柠檬烯在制备治疗非吸烟肺癌药物中的应用 |
-
2019
- 2019-12-19 CN CN201911320522.9A patent/CN111041102A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04351950A (ja) * | 1991-05-30 | 1992-12-07 | Mitsubishi Electric Corp | 臭気感応材料 |
CN101095944A (zh) * | 2007-07-10 | 2008-01-02 | 上海市肿瘤研究所 | 一种预防和治疗前列腺炎穴位缓释贴片及其制品、制备方法和用途 |
CN106727450A (zh) * | 2016-12-29 | 2017-05-31 | 上海交通大学医学院 | 右旋柠檬烯在制备治疗非吸烟肺癌药物中的应用 |
Non-Patent Citations (2)
Title |
---|
HUANBIAO MO等: ""The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins"" * |
黄巧娟等: ""D-柠檬烯抗癌机制的研究进展"" * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111956632A (zh) * | 2020-09-27 | 2020-11-20 | 上海市同仁医院 | 一种抗肿瘤的组合物及其应用 |
CN111956632B (zh) * | 2020-09-27 | 2022-10-18 | 上海市同仁医院 | 一种抗肿瘤的组合物及其应用 |
CN114107493A (zh) * | 2021-03-29 | 2022-03-01 | 上海市同仁医院 | 一种筛选对于右旋柠檬烯治疗敏感的肺腺癌患者的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105886535A (zh) | 核酸向细胞的胞外体转移 | |
CN105296430B (zh) | 一种人类结肠癌细胞系dxh-1及其应用 | |
CN111041102A (zh) | 一种对d-柠檬烯混合物抗肿瘤活性敏感患者的筛选方法 | |
CN106834290A (zh) | 一种环状rna及其用途 | |
CN108179194A (zh) | 一种肿瘤分子标志物circBIRC6及其抑制剂和用途 | |
CN106222141B (zh) | Nk细胞培养液和细胞培养方法 | |
CN107586781A (zh) | 肝癌标志物lncRNA ENST00000620463.1及其应用 | |
CN113243446A (zh) | 一种谷糠蛋白提取物及其制备方法和应用 | |
CN102552935A (zh) | 肝细胞核因子1α治疗慢性肝病的用途 | |
CN109536497A (zh) | 日本血吸虫感染及其组分在人类肿瘤预防和治疗中的应用 | |
CN109504766A (zh) | miRNA标志物miRNA-345-3p的应用 | |
CN107540736B (zh) | 与宫颈癌顺药性相关的生物大分子nherf1及其应用 | |
CN108384757A (zh) | 一种制备人胆囊癌奥沙利铂耐药细胞系的方法 | |
Yang et al. | Cisatracurium inhibits the proliferation, migration and invasion of breast cancer cells by regulating the expression of miR-3174 | |
CN113995753A (zh) | 一种中药分子槐果碱在制备治疗胶质母细胞瘤药物上的应用 | |
Duan et al. | Mesenchymal stem cell exosomes inhibit nucleus pulposus cell apoptosis via the miR-125b-5p/TRAF6/NF-κB pathway axis: Exosomes attenuate disc degeneration through the miR-125b/TRAF6/NF-κB axis | |
CN113599412A (zh) | 党参黄芪组合物在制备预防和治疗晚期肿瘤相关症状的药物中的用途 | |
CN113648306A (zh) | 佛手柑素在预防或治疗骨质疏松和/或骨丢失中的应用 | |
CN112410301A (zh) | 一种体外构建的精准预测卵巢癌患者用药的方法 | |
CN110538173A (zh) | 异硫氰酸酯类化合物在制备食管癌靶向药中的应用 | |
CN114107493A (zh) | 一种筛选对于右旋柠檬烯治疗敏感的肺腺癌患者的方法 | |
US10004713B2 (en) | Uses of chlorogenic acid in the preparation of medicaments for treatment of oligodendroglioma | |
CN111407758A (zh) | 斑蝥素作为miR-214-3p/Wnt/β-Catenin信号通路抑制剂防治骨肉瘤的用途 | |
CN115645453B (zh) | 参芪扶正注射液与nmn的组合物在制备抗肿瘤药物上的应用 | |
Xu et al. | Effect of miR-200c on nasopharyngeal carcinoma and the probable molecular regulatory mechanism involved |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Qian Biyun Inventor after: Zhu Tengteng Inventor after: Yang Yuqing Inventor after: Feng Tienan Inventor after: Li Qiang Inventor before: Qian Biyun Inventor before: Feng Tienan Inventor before: Li Qiang Inventor before: Yang Yuqing Inventor before: Zhu Tengteng Inventor before: Zhang Qi |